Predictive Oncology Receivables 2010-2025 | POAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Predictive Oncology receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Predictive Oncology receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$46.8B
Tempus AI (TEM)	$13.3B
Doximity (DOCS)	$12.6B
Hims & Hers Health (HIMS)	$10.2B
IRhythm Technologies (IRTC)	$5.4B
Hinge Health (HNGE)	$4.3B
Inspire Medical Systems (INSP)	$2.7B
Privia Health (PRVA)	$2.6B
Heartflow (HTFL)	$2.5B
Phreesia (PHR)	$1.8B
Enovis (ENOV)	$1.8B
10x Genomics (TXG)	$1.7B
Omnicell (OMCL)	$1.5B
Schrodinger (SDGR)	$1.4B
Azenta (AZTA)	$1.4B
Clover Health Investments (CLOV)	$1.4B
Claritev (CTEV)	$1.2B
Evolent Health (EVH)	$1.1B
Fulgent Genetics (FLGT)	$657M
Zepp Health (ZEPP)	$585M
Veradigm (MDRX)	$536M
Standard BioTools (LAB)	$493M
Talkspace (TALK)	$447M
Butterfly Network (BFLY)	$400M
Carlsmed (CARL)	$365M
TruBridge (TBRG)	$300M
Outset Medical (OM)	$251M
Health Catalyst (HCAT)	$246M
SOPHiA GENETICS SA (SOPH)	$228M
Nyxoah SA (NYXH)	$218M